Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival.
To examine the prevalence of and survival rates for coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), data were analyzed from all HIV-infected patients tested for HCV antibody from January 1992 until May 1997. The prevalence of HCV infection among 350 HIV-infected patients was 33%. By univariate analysis, HCV-positive (HCV+) patients were more likely to be older (P = .003), be positive for hepatitis B core antibody (P = .006), be black (P = .001), be intravenous drug users (P = .001), and have an abnormal level of aspartate aminotransferase (AST) (P = .001). In a logistic regression model, only intravenous drug abuse and abnormal AST level remained independently associated with HCV positivity. Length of survival, as determined by the Cox proportional hazards model, was similar for HCV+ vs. HCV- patients when analyzed for three different endpoints: time from diagnosis of HIV to diagnosis of AIDS, time from diagnosis of HIV to death, and time from diagnosis of AIDS to death. The prevalence of HCV infection in this population is high but does not appear to affect HIV progression or survival.
Staples
C T
CT
Veterans Affairs Medical Center, and Rollins School of Public Health, Emory University School of Medicine, Atlanta, Georgia 30033, USA.
Rimland
D
D
Dudas
D
D
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005845:Georgia / Q000453:epidemiology; D006526:Hepatitis C / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality; D006787:Hospitals, Veterans; D006801:Humans; D008297:Male; D008875:Middle Aged; D017741:Survivors; D014481:United States / Q000453:epidemiology; D014728:Veterans
D000998:Antiviral Agents